Thermo Fisher (TMO) Scientific announced the U.S. Food and Drug Administration, FDA, has approved the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic assay for use as a companion diagnostic for Dizal’s ZEGFROVY and in tumor profiling. This approval brings rapid next-generation sequencing to decentralized clinical settings closer to where patients receive care.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher’s Strategic Acquisition Adjustment Enhances Financial Prospects and Justifies Buy Rating
- NIH directs staff not to end any extra research projects for now, NY Times says
- Adial Pharmaceuticals secures U.S.-based manufacturing through agreements
- Thermo Fisher price target lowered to $450 from $475 at Barclays
- Thermo Fisher’s Strategic Divestment and Acquisition Plans Justify Buy Rating